antipsychotic drugs, creating their market

[Guest guest]

*/Side Effects May Include Lawsuits

/*By DUFF WILSON

http://www.nytimes.com/2010/10/03/business/03psych.html

For decades, antipsychotic drugs were a niche product. Today, they're

the top-selling class of pharmaceuticals in America, generating annual

revenue of about $14.6 billion and surpassing sales of even blockbusters

like heart-protective statins.

While the effectiveness of antipsychotic drugs in some patients remains

a matter of great debate, how these drugs became so ubiquitous and

profitable is not. Big Pharma got behind them in the 1990s, when they

were still seen as treatments for the most serious mental illnesses,

like hallucinatory schizophrenia, and recast them for much broader uses,

according to previously confidential industry documents that have been

produced in a variety of court cases.

Anointed with names like Abilify and Geodon, the drugs were given to a

broad swath of patients, from preschoolers to octogenarians. Today, more

than a half-million youths take antipsychotic drugs, and fully

one-quarter of nursing-home residents have used them. Yet recent

government warnings say the drugs may be fatal to some older patients

and have unknown effects on children...

- - - -

*/Child's Ordeal Shows Risks of Psychosis Drugs for Young/*

By DUFF WILSON

http://www.nytimes.com/2010/09/02/business/02kids.html

....His mother shared his medical records to help document a public

glimpse into a trend that some psychiatric experts say they are finding

increasingly worrisome: ready prescription-writing by doctors of more

potent drugs to treat extremely young children, even infants, whose

conditions rarely require such measures.

More than 500,000 children and adolescents in America are now taking

antipsychotic drugs, according to a September 2009 report by the Food

and Drug Administration. Their use is growing not only among older

teenagers, when schizophrenia is believed to emerge, but also among tens

of thousands of preschoolers...

- - - -

text: */Autism: The Diagnosis, Treatment, & Etiology of the Undeniable

Epidemic/*

W. Oller, Jr., Ph.D. and D. Oller, Ph.D.

Available here

<http://www.amazon.com/Autism-Diagnosis-Treatment-Etiology-Undeniable/dp/0763752\

800>

or here

<http://search.barnesandnoble.com/Autism/Oller-Jr--W/e/9780763752804>

Comment: The book's various topics are supported by numerous citations

which include peer-reviewed medical studies and government documents. Of

profound significance is Oller and Oller's Chapter 4, which documents

officials' ongoing coverup of thimerosal's adverse effects, despite a

growing body of research to the contrary. Indeed, the Ollers call

attention to two " streams " of information, one created by researchers

and spokespersons affiliated with producing, marketing, and injecting

vaccines, the other generated by researchers untainted by such

affiliations. In other words, the authors dare compare the medical

industry's fictional " science " with independent researchers' findings

contrary to decreed orthodoxy. The chicanery and skullduggery of the

CDC, IOM, and the journal " Pediatrics " are excellently delineated. Given

what is known about thimerosal's adverse effects in children (eg,

Verstraeten et al 1999, CDC, unpublished, reviewed here

<http://www.safeminds.org/research/Analysis%20and%20Critique%20of%20the%20CDC%27\

s%20Handling%20of%20the%20Thimerosal%20Exposure%20Assessment%20Based%20on%20VSD%\

20Information.pdf>

and here

<http://www.safeminds.org/research/library/GenerationZeroNotes.pdf>),

effects which are augmented by co-injection with the MMR (Chen et al

1997 here <http://www.ncbi.nlm.nih.gov/pubmed/9164767>), the marketing

of antipsychotics seems an anticipated ramification of vaccine

ingredients and vaccination policies.

If used in schools, the text will get instructors into trouble with

administrators. Regardless, the text is an incredibly useful source of

rebuttals, of points to add when posting replies to media. The book is

well worth the $45 and makes a invaluably functional companion to books

by Olmsted and Blaxill, Wakefield, Kirby, and R. Lathe.

*//*